Radius Health Inc. (NASDAQ:RDUS)’s share price traded up 3.5% during trading on Tuesday . The stock traded as high as $49.03 and last traded at $48.67, with a volume of 657,222 shares changing hands. The stock had previously closed at $47.01.

Several equities analysts have commented on the company. Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a report on Tuesday, July 5th. Canaccord Genuity reaffirmed a “buy” rating on shares of Radius Health in a report on Tuesday, May 31st. HC Wainwright assumed coverage on Radius Health in a report on Monday, May 23rd. They issued a “buy” rating and a $55.00 price target for the company. Finally, Cowen and Company assumed coverage on Radius Health in a report on Friday, May 6th. They issued an “outperform” rating for the company. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $70.07.

The firm’s market capitalization is $2.11 billion. The firm’s 50 day moving average price is $40.04 and its 200-day moving average price is $35.17.

Radius Health (NASDAQ:RDUS) last posted its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by $0.20. The business’s revenue was up .0% compared to the same quarter last year. During the same period last year, the company posted ($0.47) earnings per share. Equities analysts anticipate that Radius Health Inc. will post ($3.71) earnings per share for the current fiscal year.

Other large investors have recently modified their holdings of the company. Dimensional Fund Advisors LP purchased a new stake in shares of Radius Health during the fourth quarter worth about $1,362,000. Nationwide Fund Advisors boosted its stake in shares of Radius Health by 1.8% in the fourth quarter. Nationwide Fund Advisors now owns 24,238 shares of the biopharmaceutical company’s stock worth $1,492,000 after buying an additional 437 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Radius Health by 12.8% in the fourth quarter. Rhumbline Advisers now owns 31,671 shares of the biopharmaceutical company’s stock worth $1,949,000 after buying an additional 3,585 shares in the last quarter. Swiss National Bank boosted its stake in shares of Radius Health by 1.7% in the fourth quarter. Swiss National Bank now owns 36,100 shares of the biopharmaceutical company’s stock worth $2,222,000 after buying an additional 600 shares in the last quarter. Finally, Mutual of America Capital Management LLC boosted its stake in shares of Radius Health by 18.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 36,483 shares of the biopharmaceutical company’s stock worth $2,245,000 after buying an additional 5,683 shares in the last quarter.

Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.